Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in hospitalized patients with SARS-CoV-2 infection
2020-001472-14Phase 2Terminated
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pamrevlumab in coronavirus disease 2019 (COVID-19) and airway morbidity (2 arms), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Change from baseline in PaO2/FiO2 ratio. Started Apr 2020; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
coronavirus disease 2019 (COVID-19)airway morbidity
Beyond the preview
Go deeper on 2020-001472-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001472-14.